{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:04:50Z","timestamp":1793228690895,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Surg Endosc"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s00464-023-10371-9","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T17:01:53Z","timestamp":1693328513000},"page":"9366-9372","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Gastric development of pancreatic acinar cell metaplasia after Vonoprazan therapy in rats"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7787-2438","authenticated-orcid":false,"given":"Rodrigo C. L.","family":"Edelmuth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Riascos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hala","family":"Al Asadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques A.","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileana C.","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haythem","family":"Najah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl V.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice H.","family":"Schnoll-Sussman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan M.","family":"Finnerty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Fahey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasa","family":"Zarnegar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,29]]},"reference":[{"issue":"8","key":"10371_CR1","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.cgh.2012.02.028","volume":"10","author":"J Dent","year":"2012","unstructured":"Dent J et al (2012) Systematic review: patterns of reflux-induced symptoms and esophageal endoscopic findings in large-scale surveys. Clin Gastroenterol Hepatol 10(8):863-873.e3","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10371_CR2","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1053\/j.gastro.2018.08.063","volume":"156","author":"AF Peery","year":"2019","unstructured":"Peery AF et al (2019) Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology 156(1):254-272.e11","journal-title":"Gastroenterology"},{"issue":"20","key":"10371_CR3","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMra2000328","volume":"383","author":"R Mittal","year":"2020","unstructured":"Mittal R, Vaezi MF (2020) Esophageal motility disorders and gastroesophageal reflux disease. N Engl J Med 383(20):1961\u20131972","journal-title":"N Engl J Med"},{"issue":"4","key":"10371_CR4","doi-asserted-by":"publisher","first-page":"437","DOI":"10.2165\/11599320-000000000-00000","volume":"72","author":"N Vakil","year":"2012","unstructured":"Vakil N (2012) Prescribing proton pump inhibitors: is it time to pause and rethink? Drugs 72(4):437\u2013445","journal-title":"Drugs"},{"issue":"4","key":"10371_CR5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/1756283X12437358","volume":"5","author":"JJ Heidelbaugh","year":"2012","unstructured":"Heidelbaugh JJ et al (2012) Overutilization of proton-pump inhibitors: what the clinician needs to know. Ther Adv Gastroenterol 5(4):219\u2013232","journal-title":"Ther Adv Gastroenterol"},{"key":"10371_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejim.2016.10.007","volume":"37","author":"V Savarino","year":"2017","unstructured":"Savarino V et al (2017) The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal. Eur J Intern Med 37:19\u201324","journal-title":"Eur J Intern Med"},{"issue":"1","key":"10371_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12916-017-0804-x","volume":"15","author":"R Yadlapati","year":"2017","unstructured":"Yadlapati R, Kahrilas PJ (2017) When is proton pump inhibitor use appropriate? BMC Med 15(1):36","journal-title":"BMC Med"},{"issue":"2","key":"10371_CR8","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1001\/jamainternmed.2015.7927","volume":"176","author":"AJ Schoenfeld","year":"2016","unstructured":"Schoenfeld AJ, Grady D (2016) Adverse effects associated with proton pump inhibitors. JAMA Intern Med 176(2):172\u2013174","journal-title":"JAMA Intern Med"},{"issue":"7","key":"10371_CR9","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/apt.13121","volume":"41","author":"H Jenkins","year":"2015","unstructured":"Jenkins H et al (2015) Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 41(7):636\u2013648","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10371_CR10","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40262-015-0326-7","volume":"55","author":"H Echizen","year":"2016","unstructured":"Echizen H (2016) The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 55(4):409\u2013418","journal-title":"Clin Pharmacokinet"},{"key":"10371_CR11","doi-asserted-by":"publisher","first-page":"4815","DOI":"10.2147\/DDDT.S276704","volume":"14","author":"F Chen","year":"2020","unstructured":"Chen F et al (2020) In Vitro and in vivo rat model assessments of the effects of vonoprazan on the pharmacokinetics of venlafaxine. Drug Des Dev Ther 14:4815\u20134824","journal-title":"Drug Des Dev Ther"},{"issue":"4","key":"10371_CR12","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40265-015-0368-z","volume":"75","author":"KP Garnock-Jones","year":"2015","unstructured":"Garnock-Jones KP (2015) Vonoprazan: first global approval. Drugs 75(4):439\u2013443","journal-title":"Drugs"},{"issue":"6","key":"10371_CR13","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/s41401-019-0353-2","volume":"41","author":"WM Kong","year":"2020","unstructured":"Kong WM et al (2020) Physiologically based pharmacokinetic-pharmacodynamic modeling for prediction of vonoprazan pharmacokinetics and its inhibition on gastric acid secretion following intravenous\/oral administration to rats, dogs and humans. Acta Pharmacol Sin 41(6):852\u2013865","journal-title":"Acta Pharmacol Sin"},{"issue":"3","key":"10371_CR14","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1124\/jpet.111.179556","volume":"337","author":"Y Hori","year":"2011","unstructured":"Hori Y et al (2011) A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther 337(3):797\u2013804","journal-title":"J Pharmacol Exp Ther"},{"key":"10371_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jchromb.2017.05.013","volume":"1059","author":"Y Qiao","year":"2017","unstructured":"Qiao Y et al (2017) Study on pharmacokinetics and bioequivalence of Vonoprazan pyroglutamate in rats by liquid chromatography with tandem mass spectrometry. J Chromatogr B 1059:56\u201365","journal-title":"J Chromatogr B"},{"issue":"6","key":"10371_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2015.18","volume":"6","author":"Y Sakurai","year":"2015","unstructured":"Sakurai Y et al (2015) Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (Vonoprazan) doses in healthy male Japanese\/non-Japanese subjects. Clin Transl Gastroenterol 6(6):e94","journal-title":"Clin Transl Gastroenterol"},{"issue":"1","key":"10371_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00228-017-2324-1","volume":"74","author":"T Suzuki","year":"2018","unstructured":"Suzuki T et al (2018) Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin. Eur J Clin Pharmacol 74(1):45\u201352","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"10371_CR18","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s12325-016-0374-x","volume":"33","author":"Y Sakurai","year":"2016","unstructured":"Sakurai Y et al (2016) Pharmacokinetics and safety of triple therapy with vonoprazan, amoxicillin, and clarithromycin or metronidazole: a phase 1, open-label, randomized, crossover study. Adv Ther 33(9):1519\u20131535","journal-title":"Adv Ther"},{"issue":"6","key":"10371_CR19","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/apt.13325","volume":"42","author":"Y Sakurai","year":"2015","unstructured":"Sakurai Y et al (2015) Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects\u2013a randomised open-label cross-over study. Aliment Pharmacol Ther 42(6):719\u2013730","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10371_CR20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s40261-016-0488-6","volume":"37","author":"H Jenkins","year":"2017","unstructured":"Jenkins H, Jenkins R, Patat A (2017) Effect of multiple oral doses of the potent CYP3A4 inhibitor clarithromycin on the pharmacokinetics of a single oral dose of vonoprazan: a phase I, open-label, sequential design study. Clin Drug Investig 37(3):311\u2013316","journal-title":"Clin Drug Investig"},{"key":"10371_CR21","volume-title":"The laboratory rat","author":"M Suckow","year":"2019","unstructured":"Suckow M et al (2019) The laboratory rat. Elsevier, Amsterdam"},{"issue":"5","key":"10371_CR22","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00428-013-1471-8","volume":"463","author":"NI Schneider","year":"2013","unstructured":"Schneider NI et al (2013) Pancreatic acinar cells: a normal finding at the gastroesophageal junction? Data from a prospective Central European multicenter study. Virchows Arch 463(5):643\u2013650","journal-title":"Virchows Arch"},{"issue":"12","key":"10371_CR23","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1097\/00000478-199612000-00010","volume":"20","author":"HH Wang","year":"1996","unstructured":"Wang HH et al (1996) Prevalence and significance of pancreatic acinar metaplasia at the gastroesophageal junction. Am J Surg Pathol 20(12):1507\u20131510","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10371_CR24","doi-asserted-by":"publisher","first-page":"510","DOI":"10.5858\/arpa.2018-0152-OA","volume":"143","author":"S Al Salihi","year":"2019","unstructured":"Al Salihi S et al (2019) Pancreatic acinar metaplasia in distal esophageal biopsies is associated with chronic nonsteroidal anti-inflammatory drug use. Arch Pathol Lab Med 143(4):510\u2013512","journal-title":"Arch Pathol Lab Med"},{"issue":"8","key":"10371_CR25","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1097\/00000478-200208000-00008","volume":"26","author":"JN Glickman","year":"2002","unstructured":"Glickman JN et al (2002) Morphology of the cardia and significance of carditis in pediatric patients. Am J Surg Pathol 26(8):1032\u20131039","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10371_CR26","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1097\/00000478-199510000-00007","volume":"19","author":"S Krishnamurthy","year":"1995","unstructured":"Krishnamurthy S, Dayal Y (1995) Pancreatic metaplasia in Barrett\u2019s esophagus. An immunohistochemical study. Am J Surg Pathol 19(10):1172\u20131180","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"10371_CR27","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1136\/jcp.53.8.619","volume":"53","author":"HM el-Zimaity","year":"2000","unstructured":"el-Zimaity HM et al (2000) The gastric cardia in gastro-oesophageal disease. J Clin Pathol 53(8):619\u2013625","journal-title":"J Clin Pathol"},{"issue":"4","key":"10371_CR28","first-page":"137","volume":"41","author":"A Chlumsk\u00e1","year":"2005","unstructured":"Chlumsk\u00e1 A et al (2005) Autoimmune gastritis. A clinicopathologic study of 25 cases. Cesk Patol 41(4):137\u201342","journal-title":"Cesk Patol"},{"issue":"7","key":"10371_CR29","doi-asserted-by":"publisher","first-page":"854","DOI":"10.5858\/2003-127-854-PACMIA","volume":"127","author":"NC Jhala","year":"2003","unstructured":"Jhala NC et al (2003) Pancreatic acinar cell metaplasia in autoimmune gastritis. Arch Pathol Lab Med 127(7):854\u2013857","journal-title":"Arch Pathol Lab Med"},{"issue":"8","key":"10371_CR30","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1080\/00365520510015692","volume":"40","author":"J Johansson","year":"2005","unstructured":"Johansson J et al (2005) Prevalence of precancerous and other metaplasia in the distal oesophagus and gastro-oesophageal junction. Scand J Gastroenterol 40(8):893\u2013902","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"10371_CR31","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s10620-006-9253-7","volume":"52","author":"T Hagiwara","year":"2007","unstructured":"Hagiwara T et al (2007) Development of pancreatic acinar cell metaplasia after successful administration of omeprazole for 6 months in rats. Dig Dis Sci 52(5):1219\u20131224","journal-title":"Dig Dis Sci"},{"issue":"7","key":"10371_CR32","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1007\/s10620-016-4100-y","volume":"61","author":"J Matsukawa","year":"2016","unstructured":"Matsukawa J et al (2016) Radiographic localization study of a novel potassium-competitive acid blocker, vonoprazan, in the rat gastric mucosa. Dig Dis Sci 61(7):1888\u20131894","journal-title":"Dig Dis Sci"},{"issue":"4","key":"10371_CR33","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2169\/internalmedicine.3715-19","volume":"59","author":"K Kubo","year":"2020","unstructured":"Kubo K et al (2020) Vonoprazan-associated gastric mucosal redness: a report of four cases. Intern Med 59(4):507\u2013511","journal-title":"Intern Med"},{"issue":"1","key":"10371_CR34","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jcmgh.2017.03.006","volume":"4","author":"JC Mills","year":"2017","unstructured":"Mills JC, Goldenring JR (2017) Metaplasia in the stomach arises from gastric chief cells. Cell Mol Gastroenterol Hepatol 4(1):85\u201388","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"7","key":"10371_CR35","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/ncb3541","volume":"19","author":"M Leushacke","year":"2017","unstructured":"Leushacke M et al (2017) Lgr5-expressing chief cells drive epithelial regeneration and cancer in the oxyntic stomach. Nat Cell Biol 19(7):774\u2013786","journal-title":"Nat Cell Biol"},{"issue":"3","key":"10371_CR36","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1053\/j.gastro.2019.09.037","volume":"158","author":"J Burclaff","year":"2020","unstructured":"Burclaff J et al (2020) Proliferation and differentiation of gastric mucous neck and chief cells during homeostasis and injury-induced metaplasia. Gastroenterology 158(3):598-609.e5","journal-title":"Gastroenterology"},{"issue":"1","key":"10371_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1053\/j.gastro.2011.09.050","volume":"142","author":"WJ Huh","year":"2012","unstructured":"Huh WJ et al (2012) Tamoxifen induces rapid, reversible atrophy, and metaplasia in mouse stomach. Gastroenterology 142(1):21-24.e7","journal-title":"Gastroenterology"},{"issue":"1","key":"10371_CR38","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/s41598-020-57612-8","volume":"10","author":"YSH Yang","year":"2020","unstructured":"Yang YSH et al (2020) Long-term proton pump inhibitor administration caused physiological and microbiota changes in rats. Sci Rep 10(1):866","journal-title":"Sci Rep"},{"issue":"6","key":"10371_CR39","first-page":"624","volume":"4","author":"P Sengupta","year":"2013","unstructured":"Sengupta P (2013) The laboratory rat: relating its age with human\u2019s. Int J Prev Med 4(6):624\u2013630","journal-title":"Int J Prev Med"}],"container-title":["Surgical Endoscopy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00464-023-10371-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00464-023-10371-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00464-023-10371-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T04:38:47Z","timestamp":1704775127000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00464-023-10371-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10371"],"URL":"https:\/\/doi.org\/10.1007\/s00464-023-10371-9","relation":{},"ISSN":["0930-2794","1432-2218"],"issn-type":[{"value":"0930-2794","type":"print"},{"value":"1432-2218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,29]]},"assertion":[{"value":"31 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Rasa Zarnegar works as a consultant for Bard (BD). Dr. Philip Katz works as a consultant for Phathom Pharma. Rodrigo C.L. Edelmuth, Maria Cristina Riascos, Hala Al Asad, Haythem Najah, Jacques A. Greenberg, Ileana C. Miranda, Carl V. Crawford, Felice H Schnoll-Sussman, Philip O. Katz, Brendan M. Finnerty, Thomas J. Fahey III have no conflicts of interest or financial ties to disclose. The Laboratory of Comparative Pathology is supported the NCI Cancer Center Support Grant P30 CA008748.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}